Surgery may add months or years of survival for adults with rare and deadly brain cancers

by Amy Mone,Johns Hopkins UniversityCredit: Alicia Ortega, MSFor adult patients with brainstem high-grade gliomas—one of the rarest and deadliest forms of brain cancer—surgically removing the en

Updated on: December 20,2023

Surgery may add months or years of survival for adults with rare and deadly brain cancers

by Amy Mone,Johns Hopkins UniversityCredit: Alicia Ortega, MSFor adult patients with brainstem high-grade gliomas—one of the rarest and deadliest forms of brain cancer—surgically removing the en

Updated on:December 20,2023

Timing androgen-deprivation therapy with radiation therapy improves outcomes in localized prostate cancer

byUniversity of California, Los AngelesUnadjusted Kaplan-Meier and cumulative incidence curves evaluating the associations between concurrent/adjuvant versus neoadjuvant/concurrent ADT sequencin

Updated on: December 20,2023

Timing androgen-deprivation therapy with radiation therapy improves outcomes in localized prostate cancer

byUniversity of California, Los AngelesUnadjusted Kaplan-Meier and cumulative incidence curves evaluating the associations between concurrent/adjuvant versus neoadjuvant/concurrent ADT sequencin

Updated on:December 20,2023

Talquetamab Adverse Event Management in Myeloma Requires Early Oral, Dermatologic Interventions

August 25, 2022Lindsay FischerPatients with multiple myeloma can mitigate the common oral and dermatologic toxicities associated with talquetamab with early intervention tactics.Effective methods of m

Updated on: October 24,2023

Talquetamab Adverse Event Management in Myeloma Requires Early Oral, Dermatologic Interventions

August 25, 2022Lindsay FischerPatients with multiple myeloma can mitigate the common oral and dermatologic toxicities associated with talquetamab with early intervention tactics.Effective methods of m

Updated on:October 24,2023

Routine HPV testing may be warranted for sinonasal cancers

(HealthDay)—Only one in four patients with sinonasal squamous cell carcinoma (SNSCC) is tested for human papillomavirus (HPV), according to a study published online Dec. 30 inCancer.Jamie R. Oli

Updated on: December 20,2023

Routine HPV testing may be warranted for sinonasal cancers

(HealthDay)—Only one in four patients with sinonasal squamous cell carcinoma (SNSCC) is tested for human papillomavirus (HPV), according to a study published online Dec. 30 inCancer.Jamie R. Oli

Updated on:December 20,2023

Sleep disturbances are underappreciated in prostate cancer survivorship

by Tim Baker, Prostate Cancer Foundation of AustraliaCredit: CC0 Public DomainWe all got the memo that sleep is foundational for good health, right?Yet, it remains easy to overlook the importance of&n

Updated on: January 04,2024

Sleep disturbances are underappreciated in prostate cancer survivorship

by Tim Baker, Prostate Cancer Foundation of AustraliaCredit: CC0 Public DomainWe all got the memo that sleep is foundational for good health, right?Yet, it remains easy to overlook the importance of&n

Updated on:January 04,2024

Investigators explore impact of cigarette smoking and alcohol consumption on Black breast cancer survivors

by Rutgers Cancer Institute of New JerseyCredit: Unsplash/CC0 Public DomainInvestigators from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehe

Updated on: December 20,2023

Investigators explore impact of cigarette smoking and alcohol consumption on Black breast cancer survivors

by Rutgers Cancer Institute of New JerseyCredit: Unsplash/CC0 Public DomainInvestigators from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehe

Updated on:December 20,2023

AI tackles the ABCD of skin cancer

by David Bradley,InderscienceCredit: Unsplash/CC0 Public DomainNew research from India has shown how machine learning, colloquially known as artificial intelligence or AI, could improve the earl

Updated on: January 04,2024

AI tackles the ABCD of skin cancer

by David Bradley,InderscienceCredit: Unsplash/CC0 Public DomainNew research from India has shown how machine learning, colloquially known as artificial intelligence or AI, could improve the earl

Updated on:January 04,2024

CAR T cell therapy for T cell lymphoma shows promise in phase I trial

by Molly Chiu,Baylor College of MedicineCredit: Pixabay/CC0 Public DomainResearchers at the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital, and Hou

Updated on: January 26,2024

CAR T cell therapy for T cell lymphoma shows promise in phase I trial

by Molly Chiu,Baylor College of MedicineCredit: Pixabay/CC0 Public DomainResearchers at the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital, and Hou

Updated on:January 26,2024

Protein movement reveals brain tumor's weak spot

by Annika Lund,Karolinska InstitutetCredit: Unsplash/CC0 Public DomainProteins do not have a single shape, but are more like dynamic robots. But—how do they actually move? And what does this tel

Updated on: December 20,2023

Protein movement reveals brain tumor's weak spot

by Annika Lund,Karolinska InstitutetCredit: Unsplash/CC0 Public DomainProteins do not have a single shape, but are more like dynamic robots. But—how do they actually move? And what does this tel

Updated on:December 20,2023

Obesity-cancer connection discovery suggests strategies for improving immunotherapy

by Vanderbilt University Medical CenterImmunofluorescence image shows macrophages (red) in human clear cell renal cell carcinoma, the most common type of kidney cancer in adults. Credit: Jackie B

Updated on: June 15,2024

Obesity-cancer connection discovery suggests strategies for improving immunotherapy

by Vanderbilt University Medical CenterImmunofluorescence image shows macrophages (red) in human clear cell renal cell carcinoma, the most common type of kidney cancer in adults. Credit: Jackie B

Updated on:June 15,2024

FDA Approves Lymphir: A New Hope for CTCL Patients

The U.S. Food and Drug Administration (FDA) had approved Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

Updated on: August 12,2024

FDA Approves Lymphir: A New Hope for CTCL Patients

The U.S. Food and Drug Administration (FDA) had approved Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

Updated on:August 12,2024

Step-by-Step "Blood Replacement": A New ADC Therapy for Precise Tumor Elimination

Updated on: May 29,2024

Step-by-Step "Blood Replacement": A New ADC Therapy for Precise Tumor Elimination

Updated on:May 29,2024